A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.

Exclusion Criteria

• •Any of the following conditions exists: active central nervous system disease, severe active lupus nephritis, HIV infection, hepatitis B or C virus infection, low gamma globulinemia, liver dysfunction;
• •eGFR \< 30 mL/min/1.73m², or undergoing hemodialysis or kidney transplantation;
• •Pregnant women, or women who are about to become pregnant in the near future, or lactating women;
• •Participants who are simultaneously participating in other clinical studies;
• •Within 1 year before randomization, received B-cell targeted therapy (including belimumab);
• •During treatment, used traditional Chinese medicine with immunosuppressive effects (such as Tripterygium wilfordii, White Peony Root, etc.) in combination.